Dermorphin
Overview
Dermorphin is a heptapeptide opioid agonist originally isolated from the skin of South American Phyllomedusa frogs. It exhibits high selectivity and affinity for the mu-opioid receptor, with potency approximately 30 to 40 times greater than morphine in animal models. The unique D-alanine residue at position 2 confers resistance to peptidase degradation and contributes to its prolonged analgesic activity. Its potent receptor binding has made it a valuable research tool for studying opioid receptor pharmacology.
Key Research Findings
Preclinical studies in rodents have demonstrated potent antinociceptive effects following intracerebroventricular and systemic administration. Dermorphin has been used extensively in laboratory settings to map mu-opioid receptor distribution and function. No human clinical trials have been conducted, and its use remains confined to experimental neuropharmacology research.
Intracerebroventricular, Subcutaneous injection
Research Phase
Interested in Dermorphin?
Find a verified provider experienced with Dermorphin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Dermorphin ProviderRelated Peptides
Ziconotide (Prialt)
FDA ApprovedA synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone snail Conus magus. Ziconotide selectively and reversibly blocks N-type voltage-gated calcium channels (Cav2.2) in the dorsal horn of the spinal cord, inhibiting neurotransmitter release from primary afferent nociceptive neurons. It provides analgesia without opioid receptor activation, tolerance development, or respiratory depression.
Difelikefalin (Korsuva)
FDA ApprovedA selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing peripheral analgesia and anti-pruritic effects without central opioid side effects such as euphoria, dysphoria, sedation, or addiction. Difelikefalin activates kappa receptors on peripheral sensory neurons and immune cells to reduce itch signaling and inflammation. Its restricted CNS penetration is a deliberate design feature to avoid abuse potential.
ARA-290
In Clinical TrialsA synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heteromer of the EPO receptor and the beta common receptor (CD131). Unlike EPO, ARA-290 does not stimulate erythropoiesis or promote thrombosis. It produces cytoprotective, anti-inflammatory, and tissue-reparative effects by activating the IRR on neurons, immune cells, and endothelial cells.
Palmitoylethanolamide (PEA)
Research PhaseAn endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to tissue damage and inflammation. PEA acts primarily through peroxisome proliferator-activated receptor alpha (PPAR-alpha), downregulating mast cell activation and pro-inflammatory mediator release. It also modulates the endocannabinoid system via the entourage effect, enhancing anandamide activity at CB1/CB2 receptors and TRPV1 channels without directly binding cannabinoid receptors.